Bayer AG is a diversified life sciences giant operating across pharmaceuticals, consumer health, and crop science (agriculture). The company's acquisition of Monsanto in 2018 made it a global leader in agricultural biotechnology, but the deal has proven enormously costly due to ongoing Roundup/glyphosate litigation, which has erased tens of billions in shareholder value.

Bull case: Bayer's Crop Science division is a world leader in seeds, traits, and crop protection, offering strong AgriTech exposure. The pharmaceutical pipeline includes promising oncology and cardiovascular assets. The stock trades at deeply depressed valuations, offering potential upside if litigation risk diminishes.

Bear case: Glyphosate liabilities remain a massive overhang with uncertain total costs. Key pharma blockbusters like Eylea and Xarelto face patent cliffs, threatening near-term revenue. Debt levels remain elevated post-Monsanto acquisition, and dividend sustainability is questionable. Management credibility has suffered after years of value destruction.

Bayer represents a classic deep-value turnaround play with significant risks. The AgriTech franchise remains world-class, but legal and pharmaceutical headwinds make this a high-conviction contrarian bet rather than a core holding.